Document:

Option Agreement, dated December 1, 2003

 Exhibit 10.22 
  
 DATED 1 DECEMBER 2003 
  
 (1) Cambridge Display Technology Limited 
  
 (2) CDT Oxford Ltd 
  

(3) Sumitomo Chemical Co., Ltd. 
  

  
 OPTION AGREEMENT 
  

  
 CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED FROM THIS DOCUMENT. SUCH OMISSIONS ARE NOTED BY “[**]”. AN UNREDACTED VERSION OF THIS DOCUMENT
HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION. 

 THIS OPTION AGREEMENT (this “Agreement”) is made as of December 1, 2003 (the “Effective
Date”) 
  
 BETWEEN: 
  
 Cambridge Display Technology Limited (company number 02672530) whose registered
office is at Greenwich House, Madingley Rise, Madingley Road, Cambridge CB3 0TX, England (“CDT”); 
  
 CDT Oxford Limited (company number 04421247) whose registered office is at Greenwich House, Madingley Rise, Madingley Road, Cambridge CB3 0TX, England
(“CDT Oxford”); and 
  
 Sumitomo Chemical Co. Ltd. with an
office at 27-1, Shinkawa 2-chome, Chuo-ku, Tokyo, 104-8260, Japan (“Sumitomo”). 
  
 BACKGROUND: 
  

	(A)	CDT is the owner of certain inventions relating to electroluminescent polymer devices, in respect of which CDT has obtained and made applications for patent protection in various
countries. 

  

	(B)	CDT Oxford is the owner of certain inventions relating to dendrimer materials, in respect of which CDT Oxford has obtained and made applications for patent protection in various
countries, CDT Oxford has acquired the exclusive right to sub-licence certain inventions relating to dendrimer materials, in respect of which patent protection has been obtained or applied for in various countries. 

  

	(C)	Sumitomo wishes to acquire (i) an option to a licence under CDT’s patents and patent applications to manufacture, have manufactured, use, and sell electroluminescent devices
using LEP (as defined below), and (ii) an option to a licence under CDT Oxford’s patents and patent applications and a sub-licence under the patents and patent applications to which CDT Oxford has the right to grant sub-licences (hereinafter
collectively referred to as the “CDT Oxford Background Dendrimer Intellectual Property”), to manufacture, have manufactured, use and sell the Dendrimers, Hybrids, Blends and Polymer Metal Complexes (each as defined below) and to
manufacture, have manufactured, use, and sell, electroluminescent devices using the Dendrimers, Hybrids, Blends and/or Polymer Metal Complexes and CDT and CDT Oxford are willing to grant such options upon and subject to the provisions set out in
this Agreement. 

 NOW, THEREFORE, in consideration of the foregoing, the parties hereto agree as follows: 
  

	1.	DEFINITIONS 

  
 The following terms, when capitalized herein, shall have the meanings set forth in this clause. 
  

			
	 Affiliate
	 	means, when used with reference to a specified entity, any person that directly or indirectly controls, is controlled by, or is under common control with, the specified entity. An entity
shall be deemed to control any partnership or corporation in which such entity owns or controls more than fifty percent (50%) of the partnership interests or securities having the right to vote for the management thereof;
		
	 Blend
	 	means a mixture of a host material and one or more of a Dendrimer, Hybrid or Light Emitting Metal Complex wherein light emission from the mixture arises from one or more of a Dendrimer,
Hybrid or Light Emitting Metal Complex;
		
	 Dendrimer
	 	means a molecule comprising one light emitting core and at least one conjugated and branched chain;
		
	 Hybrid
	 	means a polymer comprising at least one Dendrimer;
		
	Member of CDT Oxford’s Group	 	means CDT Oxford, CDT, the Affiliates of CDT, CDT Acquisition Group Corporation of 1151 Mandarin Forrest Drive, Jacksonville, Florida, 23332, USA (“CDT Acquisition”) and the
Affiliates of CDT Acquisition;

  

 3 

			
	 Light Emitting Metal
 Complex
	  	means an organometallic molecule which has no dendrons or conjugated chain and is not a Polymer Metal Complex;
		
	 LEP
	  	means any conjugated polymer with electro-luminescent properties;
		
	 Option A
	  	means the option granted under clause 2 hereto;
		
	 Option B
	  	means the options granted under clause 3 hereto;
		
	 Polymer Metal Complex
	  	means a polymer containing at least one light emitting metal complex that is not a Dendrimer;
		
	 Products
	  	means Dendrimers, Hybrids, Blends, Polymer Metal Complexes, Light Emitting Metal Complexes and Special Blends; and
		
	 Special Blends
	  	means a mixture of a host material and a Polymer Metal Complex wherein light emission from the mixture arises from a Polymer Metal Complex.

  

	2.	OPTION TO MATERIALS DENDRIMER LICENCE 

  

	2.1	CDT Oxford grants to Sumitomo and its Affiliates an option to a world-wide, non-exclusive licence, to manufacture, have manufactured, use, and sell Products under the CDT Oxford
Background Dendrimer Intellectual Property on the terms set out in the Patent Licence for Dendrimer Materials at Schedule 1 of this Agreement. 

  

	2.2	The option granted under clause 2.1 may be exercised by Sumitomo at any time up to the fifth anniversary of the date hereof upon 30 days prior written notice provided to CDT Oxford,
whereupon the parties shall execute the Patent Licence for Dendrimer Materials set out in Schedule 1 and Amendment to License Agreement set out in Schedule 2. 

  

 4 

	3.	OPTION TO DISPLAY LICENCE 

  

	3.1	CDT grants to Sumitomo and its Affiliates an option to a world-wide, non-exclusive licence, under its intellectual property to manufacture, have manufactured, use, and sell display
devices, including lighting devices, using LEP on terms and conditions which shall be separately agreed upon, through negotiations conducted in good faith, between CDT and Sumitomo. 

  

	3.2	CDT Oxford grants to Sumitomo and its Affiliates an option to a world-wide, non-exclusive licence, under its intellectual property to manufacture, use and sell display devices,
including lighting devices, which incorporate the Products on terms and conditions which shall be separately agreed upon, through negotiations conducted in good faith, between CDT Oxford and Sumitomo. 

  

	3.3	The options granted under clauses 3.1 and 3.2 may be exercised by Sumitomo at any time up to the third anniversary of the date hereof, upon 30 days prior written notice, at which
time the relevant parties hereto shall negotiate the terms and conditions of such license. 

  

	4.	CONSIDERATION 

  

	4.1	In consideration of the grant of Option A and Option B, Sumitomo shall pay to CDT the sum of [**] (the “Option Fee”). The Option Fee shall be non-refundable and
shall be paid within 30 days of the Effective Date. All sums payable pursuant to this Agreement are exclusive of value added tax or other applicable taxes or duties for which Sumitomo shall be additionally liable and shall be paid in cleared funds
to such bank account as CDT may from time to time nominate, without any set off, deduction or withholding except such amount (if any) of tax as Sumitomo is required to deduct or withhold by law. If Sumitomo is required by law to make any tax
deduction or withholding, Sumitomo shall do all things in its power which may be reasonably necessary to enable or assist CDT to claim exemption therefrom under any double taxation or similar agreement from time to time in force and shall from time
to time give CDT proper evidence as to the deduction or withholding and payment over of the tax deducted or withheld. 

  

	5.	TERM OF OPTIONS 

  

	5.1	This Agreement shall become effective on the Effective Date and shall remain in full force and effect until the fifth anniversary of the Effective 

  

 5 

 Date. Notwithstanding the foregoing, the parties agree that Option B shall expire on the third
anniversary of the Effective Date. 
  

	5.2	No expiration of this Agreement shall constitute a termination or waiver of any rights or obligation of any party hereto accruing at or prior to the date of expiration. In addition,
the provisions of clauses 5.2, 6.5 and 6.6 shall survive any expiration of this Agreement without limitation. 

  

	6.	NATURE OF AGREEMENT 

  

	6.1	CDT and CDT Oxford shall be entitled to transfer the monetary benefit of this Agreement by way of novation to any Member of CDT Oxford’s Group, provided that any act or
omission of any such Member of CDT Oxford’s Group shall, for all the purposes of this Agreement, be deemed to be the act or omission of CDT or CDT Oxford, whether jointly or severally. Any such transfer shall not relieve CDT or CDT Oxford, as
the case may be, from any liability or obligation arising on or prior to the date of such transfer. 

  

	6.2	CDT or CDT Oxford may transfer both the benefit and burden of this Agreement by way of a novation to any purchaser or other successor in title (whether by way of a flotation,
initial public offering, reorganisation, amalgamation or otherwise) of all or substantially all of its business. Any such transfer shall not relieve CDT or CDT Oxford, as the case may be, from any liability or obligation arising on or prior to the
date of such transfer. 

  

	6.3	This Agreement is personal to Sumitomo who shall not assign, mortgage, charge (otherwise than by floating charge) or (except as expressly provided herein) sub-license any of its
rights hereunder or sub-contract or otherwise delegate any of its obligations hereunder, unless otherwise explicitly stipulated hereunder, except with the written consent of the other parties hereto (which consent shall not be unreasonably withheld
or delayed). Notwithstanding the foregoing, the parties hereto agree that SUMITOMO shall be entitled to assign this Agreement to any of its Affiliates without any requirement to obtain the consent of CDT or CDT OXFORD. 

  

	6.4	The grant of Option A and Option B, pending their exercise, does not grant or imply to Sumitomo any licence under CDT’s or CDT Oxford’s intellectual property.

  

	6.5	This Agreement shall be governed by and construed in accordance with English law. 

  

 6 

	6.6	If it is not possible to resolve a disagreement or dispute arising under, out of, or in connection with or in relation to this Agreement through good faith negotiations among the
parties hereto, the matter shall be submitted to a panel of three arbitrators in accordance with the Rules of Arbitration of the International Chamber of Commerce. Sumitomo will chose one arbitrator and CDT and CDT Oxford shall jointly choose the
second arbitrator. The third arbitrator shall be selected by the first two arbitrators. The arbitration shall take place in Tokyo, Japan, if requested by CDT or CDT Oxford, and in London, England, if requested by Sumitomo. The parties hereto agree
that service of any notices in the course of such arbitration at their addresses as given in this Agreement shall be valid and sufficient. Any award rendered in such arbitration shall be final and binding upon the parties hereto, and judgment upon
the award rendered in the arbitration may be entered in any court having jurisdiction, or application may be made to such court for a judicial acceptance of the award and an order of enforcement, as the case may be. 

  

	7.	MISCELLANEOUS 

  

	7.1	Any notice, disclosure or report given under this Agreement shall be in writing (which for such purposes shall include e-mail), in English and legible, shall be served by hand on a
business day at or by being sent by facsimile (with confirmation of receipt) or email on a business day or by being sent by first class post or airmail to the address as given on page 1 or as otherwise notified in accordance with this clause, and
shall be deemed served on the date actually received by the other party. Notices, disclosures and reports shall, if sent to CDT OXFORD, be marked for the attention of Stephen Chandler, Director Legal & IP and, if sent to SUMITOMO, shall be
marked for the attention of Toshihiro Ohnishi, Corporate Planning & Coordination Office or, in either case, such other person whose details have been notified in accordance with this clause. 

  

	7.2	To the extent that any provision of this Agreement is found by any court or competent authority to be invalid, unlawful or unenforceable in any jurisdiction, that provision shall be
deemed not to be a part of this Agreement, it shall not affect the enforceability of the remainder of this Agreement nor shall it affect the validity, lawfulness or enforceability of that provision in any other jurisdiction.

  

	7.3	This Agreement comprises the entire agreement and understanding of the parties in relation to its subject matter and cancels and supersedes all previous communications, agreements
or understandings with regard to such subject matter. Each party hereto acknowledges that it has entered into this Agreement in reliance only upon the representations, warranties 

  

 7 

 and promises specifically contained in this Agreement. The parties hereto specifically agree that said
previous communications, agreements, representations, understandings, negotiations, proposals or undertakings shall not be admissible as evidence in any arbitration, litigation or other legal proceeding for interpretation of this Agreement.

  

	7.4	This Agreement may only be varied by an agreement in writing specifically referring to this clause 7.4 and signed by or on behalf of both parties hereto. 

 

	7.5	No delay or omission on the part of any party to this Agreement in exercising any right, power or remedy provided by law or under this Agreement shall impair such right, power or
remedy; or operate as a waiver thereof, nor shall the single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy. 

  

	7.6	The rights, powers and remedies conferred on any party by this Agreement and remedies available to any party are cumulative and are additional to any right, power or remedy which it
may have under general law, this Agreement or otherwise. 

  

	7.7	This Agreement may be executed via facsimile and may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute
one and the same instrument. 

  

	7.8	Any party may, in whole or in part, release, compound, compromise, waive or postpone, in its absolute discretion, any liability owed to it or right granted to it in this Agreement
by any other party or parties without in any way prejudicing or affecting its rights in respect of that or any other liability or right not so released, compounded, compromised, waived or postponed. 

  

 8 

 THIS AGREEMENT has been executed by the authorised signatories of each party on the Effective Date. 
  

			
	Cambridge Display Technology Limited
		
	 By:
	 	 /s/    David Fyfe

	 Name:
	 	 David Fyfe

	 Title:
	 	 CEO

  

			
	CDT Oxford Limited
		
	 By:
	 	 /s/    Ian Butcher

	 Name:
	 	 Ian Butcher

	 Title:
	 	 Chairman & Director

  

			
	Sumitomo Chemical Co., Ltd. By:
		
	 By:
	 	 /s/    Satoshi Kawachi

	 Name:
	 	 Satoshi Kawachi

	 Title:
	 	 Senior Managing Director

  

 9 

 DATED 1 DECEMBER 2003 
  
 (1) CDT Oxford Ltd 
  
 (2) Sumitomo Chemical Co., Ltd. 
  

  
 PATENT LICENCE FOR
DENDRIMER MATERIALS 
  

 THIS PATENT LICENSE FOR DENDRIMER MATERIALS is made as of [date] (the “Effective Date”)

  
 BETWEEN: 
  

	(1)	CDT Oxford Limited (company number 04421247) whose registered office is at Greenwich House, Madingley Rise, Madingley Road, Cambridge CB3 0TX, England (“CDT
Oxford”); and 

  

	(2)	Sumitomo Chemical Co., Ltd. with an office at 27-1, Shinkawa 2-chome, Chuo-ku, Tokyo, 104-8260, Japan (the “Licensee”). 

  
 BACKGROUND: 
  

	(A)	CDT Oxford is the owner of certain inventions relating to dendrimer materials, in respect of which CDT Oxford has obtained and made applications for patent protection in various
countries. 

  

	(B)	CDT Oxford has acquired the exclusive right to sub-licence certain inventions relating to dendrimer materials, in respect of which patent protection has been obtained or applied for
in various countries. 

  

	(C)	The Licensee wishes to acquire a licence under CDT Oxford’s patents and patent applications and a sub-licence under the patents and patent applications to which CDT Oxford has
the right to grant sub-licences, to manufacture, have manufactured, use and sell dendrimer materials together with hybrid and other related materials and CDT Oxford is willing to grant such a licence upon and subject to the provisions set out in
this Agreement. 

  
 NOW, THEREFORE, in consideration of the
foregoing, the parties hereto agree as follows: 
  

	1.	DEFINITIONS AND INTERPRETATION 

  

	1.1	The following terms, when capitalized herein, shall have the meanings set forth in this clause: 

  

			
	 Affiliate
	  	means, when used with reference to a specified entity, any person that directly or indirectly controls, is controlled by, or is under common control with, the specified entity. An entity
shall be deemed to control any partnership or corporation in which such entity owns or controls more than fifty percent (50%) of the partnership interests or securities having the right to vote for the management thereof;

  

 2 

			
	 Agreement
	  	means this Patent Licence for Dendrimer Materials (including any schedule or annexure to it and any amendment or modification thereto in agreed form);
		
	 Blend
	  	means a mixture of a host material and one or more of a Dendrimer, Hybrid or Light Emitting Metal Complex wherein light emission from the mixture arises from one or more of a Dendrimer or
Hybrid or Light Emitting Metal Complex;
		
	 CDT Oxford
 Background
Dendrimer
 Intellectual Property
	  	means the CDT Oxford Patents, the CDT Oxford Licensed Patents and the Technology relating to such patents;
		
	 CDT Oxford Licensed
 Patents
	  	means the patents and patent applications licensed to CDT Oxford by the University of Oxford, Isis Innovations and the University of St Andrews as listed in Schedule 2 (“Schedule 2
Patents”), which shall be updated from time to time by adding to Schedule 2 the patents and patent applications licensed to CDT Oxford after the Effective Date by the University of Oxford, Isis Innovations and the University of St Andrews
regarding Products, and any and all family members of such patents and patent applications, including (a) counterpart foreign patents and counterpart foreign patent applications of the Schedule 2 Patents (“Schedule 2 Foreign Patents”), (b)
continuations, continuations in part, divisionals, extensions, revivals, renewals, reissues, and substitutes (“Derivatives”) of the Schedule 2 Patents and the Schedule 2 Foreign Patents, (c) patents and patent applications claiming
priority from (i) the Schedule 2 Patents, (ii) the Schedule 2 Foreign Patents, and (iii) the Derivatives of the Schedule 2 Patents and the Schedule 2 Foreign Patents (“Schedule 2 Priority Patents”), and (d) the Derivatives of the Schedule
2 Priority Patents;

  

 3 

			
	 CDT Oxford Patents
	  	means the patents and patent applications listed in Schedule 1 (“Schedule 1 Patents”), which shall be updated from time to time by adding to Schedule 1 the patents and patent
applications filed by CDT Oxford after the Effective Date regarding Products, and any and all family members of such patents and patent applications, including (a) counterpart foreign patents and counterpart foreign patent applications of the
Schedule 1 Patents (“Schedule 1 Foreign Patents”), (b) the Derivatives of the Schedule 1 Patents and the Schedule 1 Foreign Patents, (c) patents and patent applications claiming priority from (i) the Schedule 1 Patents, (ii) the Schedule 1
Foreign Patents, and (iii) the Derivatives of the Schedule 1 Patents and the Schedule 1 Foreign Patents (“Schedule 1 Priority Patents”), and (d) the Derivatives of the Schedule 1 Priority Patents;
		
	 Confidential
 Information
	  	means any and all information disclosed by one party hereto to the other party hereto during the term of this Agreement (whether in writing, orally or by any other means), which at the time
of disclosure is designated as confidential or proprietary, is disclosed in circumstances of confidence, or would be understood by parties hereto, exercising reasonable business judgement, to be confidential;
		
	 Dendrimer
	  	means a molecule comprising one light emitting core and at least one conjugated and branched chain;
		
	 Disclosing Party
	  	means the party disclosing its Confidential Information to the other party;
		
	 Hybrid
	  	means a polymer comprising at least one Dendrimer;
		
	 Intellectual Property
	  	means any patent, trade or service mark (whether registered or not), copyright, registered design,

  

 4 

			
	 	  	design right and topography right or any other form of protection, any right to apply or application for such protection, and any rights in any secret process, know-how, technical reports,
designs, confidential information or otherwise or any associated or similar right or protection subsisting at the relevant time in any jurisdiction, anywhere in the world;
		
	 Light Emitting Metal
 Complex
	  	means an organometallic molecule which has no dendrons or conjugated chain and is not a Polymer Metal Complex;
		
	 Member of CDT
 Oxford’s
Group
	  	means Cambridge Display Technology Ltd whose registered office is at Greenwich House, Madingley Rise, Madingley Road, Cambridge CB3 0TX and its Affiliates and CDT Acquisition Corporation of 1151
Mandarin Forrest Drive, Jacksonville, Florida, 23332, USA and its Affiliates;
		
	Polymer Metal Complex	  	means a polymer containing at least one light emitting metal complex that is not a Dendrimer;
		
	Net Sales	  	means the gross invoice price billed by Licensee to its customers for the sale of Products after deduction of (a) duties, sales taxes, value added or similar taxes, consumption taxes and
other governmental charges actually incurred and paid by Licensee in connection with sales and delivery of such Products if included in such gross invoice price, (b) costs of packaging, transportation charges and insurance, if included in such gross
invoice price, (c) credits or allowances given or made on account of the settlement of complaints, rejection of Products, return of Products or retroactive price reductions, if included in such gross invoice price, and (d) trade, cash, or quantity
discounts allowed and taken, if included in such gross invoice price;

  

 5 

			
	 Option Agreement
	  	means the option agreement relating to the licensing of CDT Oxford Background Dendrimer Intellectual Property entered into by the parties and dated as of December 1, 2003;
		
	 Products
	  	means Dendrimers, Hybrids, Blends, Polymer Metal Complexes, Light Emitting Metal Complexes and Special Blends;
		
	 Project
	  	means the joint development work to be conducted under the Joint Development Agreement dated as of December 1, 2003, between CDT Oxford and Sumitomo.
		
	 Quarter
	  	means the three months commencing on January 1, April 1, July 1, or October 1. The first Quarter under this Agreement shall be for a period commencing as of the effective date of this
Agreement and ending at the end of March, June, September or December, whichever comes first after the effective date of this Agreement. The last Quarter under this Agreement shall end on its termination or expiry. “Quarterly” shall
be construed accordingly;
		
	 Receiving Party
	  	means the party receiving Confidential Information from the Disclosing Party;
		
	 Recipient
	  	means any employee, agent, advisor or consultant of the Receiving Party.
		
	 Special Blends
	  	means a mixture of a host material and a Polymer Metal Complex wherein light emission from the mixture arises from a Polymer Metal Complex;
		
	 Technology
	  	means any discovery, invention, development, technical information, data, knowledge, technique, process, demonstrator, system, formula, result of experiment, design, statistic, record,
know-how, information, material or substance and all Intellectual Property relating to any of the foregoing, whether the subject of a patent, or patent application, or not;

  

 6 

	1.2	As used in this Agreement, unless the context otherwise requires: 

  

	 	(a)	words in the singular include the plural and vice versa and words in one gender include any other gender; 

  

	 	(b)	a reference to a statute or statutory provision includes any statute or statutory provision which modifies, consolidates, re-enacts or supersedes it; 

  

	 	(c)	a reference to clauses and schedules is to clauses of and schedules to this Agreement and references to sub-clauses and paragraphs are references to sub-clauses and paragraphs of
the clause or schedule in which they appear; and 

  

	 	(d)	the table of contents and headings are for convenience only and shall not affect the interpretation of this Agreement. 

  

	2.	GRANT OF LICENCE 

  

	2.1	CDT Oxford grants to Licensee and to its Affiliates and Licensee accepts on behalf of itself and its Affiliates, a non-exclusive licence to use the CDT Oxford Background Dendrimer
Intellectual Property upon and subject to the provisions of this Agreement, to manufacture, have manufactured, use and sell Products in any and all countries of the world. 

  

	2.2	The Licensee shall give written notification to CDT Oxford if any of the rights granted hereunder are exercised by an Affiliate of the Licensee. Any act or omission of any such
Affiliate shall, for all purposes of this Agreement, be deemed to be the act or omission of the Licensee. 

  

	2.3	CDT Oxford shall not grant any licences under the CDT Oxford Background Dendrimer Intellectual Property to any third party for a period of two years following the date of signature
of the Option Agreement. For the avoidance of doubt CDT Oxford retains the right to grant options to licences to the CDT Oxford Background Dendrimer Intellectual Property, provided that no such options are exercisable prior to the date set forth in
this clause 2.3. 

  

 7 

	2.4	In the event that following the Effective Date CDT Oxford grants one or more licences under the CDT Oxford Background Dendrimer Intellectual Property to any third party on terms
more favourable than those granted to Licensee in this Agreement, the Licensee shall be entitled to have this Agreement modified such that the more favourable terms shall apply to this Agreement. Any such modification of this Agreement shall be
subject to the Licensee undertaking such additional or different terms and conditions as are undertaken by such third party. Any more favourable royalty rate shall only apply from the date such royalty applies to such third party. The foregoing
provision shall not apply where: 

  

	 	(a)	CDT Oxford receives a grant of patent rights, other licence or other non-monetary consideration from such third party; or 

  

	 	(b)	the more favourable terms result from the settlement of a claim by CDT Oxford. 

  

	2.5	CDT Oxford agrees not to sue Licensee or its Affiliates for contributory infringement under CDT Oxford Background Dendrimer Intellectual Property to the extent that Products
supplied by Licensee are being used by Licensee’s customers for the purposes of research and development and not for the production of products for commercial sale. CDT Oxford will promptly notify Licensee if it believes Licensee is
contributorily infringing CDT Oxford Background Dendrimer Intellectual Property by supplying a particular customer and CDT Oxford will identify such customer of Licensee. CDT Oxford will not pursue any suit against Licensee for the alleged
contributory infringement unless Licensee has not ceased sales to such customer within three months of receiving such notice from CDT Oxford. 

  

	2.6	Licensee agrees to use, and to procure that its Affiliates use, such trademarks, designs or wording in conjunction with the sale of Products as CDT Oxford reasonably directs from
time to time, such trademarks, designs or wording being intended generally to indicate such licence and/or designate the materials in question as incorporating CDT Oxford technology. The Licensee shall not use any mark or name confusingly similar to
any trademark, design, or wording that may be stipulated by CDT Oxford pursuant to this clause 2.6 or otherwise prejudice their distinctiveness or reputation. 

  

	3.	WARRANTIES AND REPRESENTATION 

  

	3.1	CDT Oxford hereby represents and warrants to Licensee that; 

  

 8 

	 	(a)	it is the sole and exclusive owner of the CDT Oxford Patents; 

  

	 	(b)	it has been granted an exclusive license from the University of Oxford, Isis Innovations and the University of St Andrews, with the right to sublicense to any third party in the
field of light emitting materials and devices, under CDT Oxford Licensed Patents and it is specifically authorized to licence the manufacture, use and sale of Products in any and all countries of the world, 

  

	3.2	Should Licensee become aware that the exercise by Licensee of any of the rights granted to it under clause 2.1 above may amount to infringement of a patent owned by a third party,
or should the exercise by Licensee of any of the rights granted to it under clause 2.1 above give rise to a claim for infringement of any patent owned by a third party, Licensee shall inform CDT Oxford of such claim and both parties will discuss how
to defend such claim. CDT Oxford agrees to provide Licensee with such reasonable assistance as is reasonably necessary to enable Licensee to defend such claim. CDT Oxford’s assistance under this clause 3.2 shall be within CDT Oxford’s
capacity then available to CDT Oxford and shall be subject to the payment of compensation (limited to fees and actual costs incurred by CDT Oxford in connection with providing such assistance) by Licensee to CDT Oxford. Notwithstanding the above,
CDT Oxford shall provide Licensee with such technical information then available to it that is reasonably necessary for the purpose of Licensee’s defending itself. 

  

	3.3	CDT Oxford does not give and nothing contained in this Agreement shall be construed as: 

  

	 	(a)	a warranty or representation by it that any patent applications licensed hereunder will proceed to grant; 

  

	 	(b)	a warranty or representation by CDT Oxford as to the volume or quality of Products which may be manufactured through the use of the CDT Oxford Background Dendrimer Intellectual
Property; 

  

	 	(c)	conferring by implication, estoppel or otherwise, upon the Licensee or any other Affiliate, any licence or other right under any patent rights or other intellectual property except
for the licenses and rights expressly granted hereunder; 

  

	 	(d)	a representation or warranty as to the efficacy or usefulness of the CDT Oxford Background Dendrimer Intellectual Property or that they will produce materials of satisfactory
quality or fit for the purpose for which the Licensee or any other Affiliate intended; 

  

 9 

	 	(e)	a warranty or representation as to the validity or scope of any patent or patent application licensed hereunder; or 

  

	 	(f)	a warranty or representation that the manufacture, use, rental, lease, sale, transfer or other disposal of any Product is free from infringement of any patents or other rights of
third parties. 

  

	4.	FINANCIAL PROVISIONS 

  

	4.1	In consideration of the rights and licenses granted by CDT Oxford to Licensee under this Agreement, the Licensee will pay to CDT Oxford: 

  

	 	(a)	the initial lump sum fee of [**], due within thirty (30) days of the Effective Date; and 

  

	 	(b)	royalties of [**] in respect of the Net Sales of all Products manufactured by or for the Licensee or any Affiliate using the CDT Oxford Background Dendrimer Intellectual Property
and sold and, in the case of any non-cash transaction, transferred to third parties, in each Quarter. 

  

	4.2	The royalties due under clause 4.1 (b) shall be paid to CDT Oxford within sixty (60) days after the end of each Quarter during the term of this Agreement. On a quarterly basis,
Licensee shall submit to CDT Oxford a written report showing: 

  

	 	(a)	the Net Sales of all Products; and 

  

	 	(b)	the amount of royalties due pursuant to clause 4.1(b). 

  

	4.3	Where any Product is sold or otherwise disposed of by means of a commercial transaction other than on arm’s length terms then the Net Sales price shall be the fair market price
for such Product. Where the parties are unable to agree on such a fair market price, Licensee shall provide a letter signed by an independent accounting firm (which is reasonably agreeable to CDT Oxford) which establishes a fair market price for
such Product, provided that all expenses incurred by Licensee in connection with providing such letter shall be borne or promptly reimbursed by CDT Oxford. 

  

	4.4	All royalties or other sums payable under this Agreement shall be paid in US Dollars (US$), and where the underlying price in respect of which any 

  

 10 

 royalty is so payable is stated in a currency other than US$, it shall be converted into US$ by reference
to the Telegraphic Transfer Selling (TTS) rate quoted from the publication by Bank of Tokyo Mitsubishi on the last business day of the Quarter in question. 
  

	4.5	All sums payable pursuant to this Agreement are exclusive of value added tax or other applicable taxes or duties for which the Licensee shall be additionally liable and shall be
paid in cleared funds to such bank account as CDT Oxford may from time to time nominate, without any set off, deduction or withholding except such amount (if any) of tax as the Licensee is required to deduct or withhold by law. If the Licensee is
required by law to make any tax deduction or withholding, the Licensee shall do all things in its power which may be reasonably necessary to enable or assist CDT Oxford to claim exemption therefrom under any double taxation or similar agreement from
time to time in force and shall from time to time give CDT Oxford proper evidence as to the deduction or withholding and payment over of the tax deducted or withheld. 

  

	4.6	If the Licensee makes any default in payment of the royalties and other sums due hereunder the amount due shall bear interest, both before and after any judgement, at the rate of
1.0% per month compounded monthly from the due date until payment is made to CDT Oxford. In no event shall said annual rate exceed the maximum interest allowed by applicable law. 

  

	4.7	At the commencement of this Agreement the Licensee will give CDT Oxford a non-binding estimate of the likely royalties payable to CDT Oxford with respect to the calendar year in
which the commencement takes place. Thereafter, in the October preceding each complete calendar year, Licensee will furnish similar non-binding information with respect to the succeeding calendar year. It is understood by both parties that such
estimate shall be used only for the purpose of CDT Oxford’s budget planning, and shall not bind Licensee in any way. 

  

	4.8	Licensee’s reports submitted to CDT Oxford pursuant to clause 4.2 above shall be certified by an officer of Licensee or by a designee of such officer to be correct to the best
of Licensee’s knowledge and information. 

  

	5.	MATERIALS 

  

	5.1	Upon CDT Oxford’s written request, Licensee shall provide free of charge a reasonable quantity of samples of Products to CDT Oxford Provided always that the Licensee is able to
manufacture such samples without unreasonable interference to its other commercial activities. CDT Oxford agrees that it shall use such samples solely for CDT Oxford’s research 

  

 11 

 purposes and that it shall not provide any third party with such samples without first obtaining the
prior written consent of Licensee, such consent not to be unreasonably withheld, except that the parties hereto agree that Licensee may withhold its consent to CDT Oxford providing such samples to Licensee’s competitors. Licensee may terminate
the requirement to provide CDT Oxford with samples upon providing CDT Oxford with six (6) months prior written notice if (a) Licensee decides not to commercialize or decides to terminate selling Products or (b) Licensee has any other reasonable
reason to terminate the requirement set forth in this clause 5.1. 
  

	5.2	Licensee agrees to negotiate a supply agreement to supply CDT Oxford and/or Members of CDT Oxford’s Group with Products for use in manufacturing light emitting devices.
Licensee agrees that such supply agreement will be on terms and conditions which, taken as a whole, are at least as favorable to CDT Oxford as the most favorable terms and conditions that Licensee has or may grant from time to time to any third
party (except if primarily in settlement of a bona fide dispute regarding any light emitting devices) with respect to Products for use in manufacturing light emitting devices. In the event that while such supply agreement with CDT Oxford is in
effect, Licensee enters an agreement of similar scope (not including an agreement that is entered primarily to settle a bona fide dispute regarding infringement of Products for use in manufacturing light emitting devices or proprietary rights
relating thereto) for less consideration with a third party, then CDT Oxford may within sixty (60) days of notice of such agreement, elect to substitute the consideration provisions of such agreement for the consideration provisions of CDT
Oxford’s supply agreement; provided, however, that CDT Oxford adopts all of the additional restrictions, obligations and supply limitations imposed in such agreement. In determining whether an agreement is of a similar scope and the
consideration is less, (a) all the terms of CDT Oxford’s supply agreement then in effect and such agreement shall be analyzed as a whole and (b) only the value and consideration attributable to Products for use in manufacturing light emitting
devices will be taken into account. 

  

	6.	ACCOUNTS 

  

	6.1	During the term of this Agreement and for a period of two (2) years thereafter, Licensee shall keep, and shall ensure that its Affiliates keep, true and detailed accounts and
records of customer invoices and books of account, in sufficient detail to enable CDT Oxford to determine the amount of royalties due and payable under this Agreement in the manner provided in clause 6.2. 

  

 12 

	6.2	The Licensee shall, at the reasonable request of CDT Oxford, allow an independent royalty auditor, no more than once per year, to inspect the records and books of Licensee
referenced in clause 6.1 above at any reasonable time during normal business hours, provided that such auditor shall only report to CDT Oxford the amount of such royalty calculation, and, provided further, that CDT Oxford shall in advance bind such
auditor through proper contractual obligations not to disclose to any third party the information obtained through such inspection or to use such information for any purpose other than the purpose set forth in this clause 6.

  

	6.3	Inspections under clause 6.2 shall be carried out at CDT Oxford’s expense. However if the audit proves that the Licensee’s accounting of royalties was deficient by more
than 5% of the money actually due, the cost of such inspection shall be borne by the Licensee. 

  

	6.4	The provisions of this clause 6 shall remain in full force and effect for two years after the termination of this Agreement. 

  

	7.	DURATION AND TERMINATION 

  

	7.1	This Agreement shall be effective as of the Effective Date and, unless sooner terminated as hereinafter set forth, shall continue in full force and effect until the later of (a) ten
(10) years from the Effective Date or (b) the expiration of the last to expire of the CDT Oxford Patents and the CDT Oxford Licensed Patents that Licensee is using for the purpose of manufacturing, using or selling Products at the end of such ten
year period. After the expiration of this Agreement, all rights and licenses granted hereunder shall remain in full force and effect on a non-exclusive basis and shall be irrevocable, and Licensee shall be free to use all CDT Oxford Background
Dendrimer Intellectual Property in connection with the use, sale and manufacture of Products without any further payments to CDT Oxford. 

  

	7.2	CDT Oxford may forthwith terminate this Agreement by written notice to the Licensee if Licensee fails to make any payment when due under this Agreement and such payment is not made
within sixty (60) days of written notice from CDT Oxford to Licensee. 

  

	7.3	Either party may forthwith terminate this Agreement by written notice to the other if: 

  

	 	(a)	the other party has materially breached this Agreement. Such termination shall be automatically effective if such breach has not been cured within thirty (30) calendar days after
written notice of the breach to the breaching party; 

  

 13 

	 	(b)	an encumbrancer takes possession of, or a receiver is appointed with respect to, any of the property or assets of the other party; 

  

	 	(c)	the other party becomes subject to an administrative order or makes any voluntary arrangement with its creditors (within the meaning of the Insolvency Act 1986) or anything
analogous to the foregoing under the law of any other jurisdiction occurs in relation to that other party; 

  

	 	(d)	the other party goes into liquidation (except for the purposes of amalgamation or reconstruction and in such manner that the company resulting therefrom effectively agrees to be
bound by or assume the obligations imposed on that other party under this Agreement); 

  
 or any analogous event to the foregoing under the applicable law of any jurisdiction occurs in relation to the other party. 
  

	7.4	For the avoidance of doubt the rights to terminate this Agreement given by this clause shall not prejudice any other right or remedy of either party in respect of the breach
concerned (if any) or any other breach. 

  

	8.	EFFECTS OF TERMINATION 

  

	8.1	On termination of this Agreement: 

  

	 	(a)	if CDT Oxford terminates this Agreement in accordance with clause 7.2 or 7.3, the Licensee shall cease to use, either directly or indirectly, the CDT Oxford Background Dendrimer
Intellectual Property (unless and to the extent expired); 

  

	 	(b)	if CDT Oxford terminates this Agreement in accordance with clause 7.2 or 7.3, the Licensee shall consent to the cancellation of any formal licence granted to it, or of any recordal
of it in any register, in relation to any of the CDT Oxford Background Dendrimer Intellectual Property; 

  

	 	(c)	No termination or expiration of this Agreement shall constitute a termination or waiver of any rights or obligation of any party hereto accruing at or prior to the date of
expiration; and 

  

 14 

	 	(d)	the provisions of clause 9 shall survive any termination or expiration of this Agreement for the time period specified therein, and the provisions of clauses 2.5, 3, 6, 7.1, 8, 11,
12, and 18 shall survive any termination or expiration of this Agreement without limitation. 

  

	9.	CONFIDENTIALITY 

  

	9.1	The Receiving Party shall keep all Confidential Information of the Disclosing Party confidential and shall not, at any time during the term of this Agreement or within 10 years from
the date of any termination or expiration of this Agreement, disclose or divulge such Confidential Information of the Disclosing Party to any other person other than with the prior written consent of the Disclosing Party, or use the Confidential
Information of the Disclosing Party for any purpose except as contemplated by this Agreement. 

  

	9.2	During the term of this Agreement, the Receiving Party may only disclose the Confidential Information of the Disclosing Party to any Recipient to the extent that it is necessary for
the purposes of this Agreement, provided that the Receiving Party shall bind, in advance, such Recipient with a proper contractual obligation not to disclose the Confidential Information of the Disclosing Party to any third party.

  

	9.3	The Confidential Information may be disclosed by the Receiving Party to any governmental or other authority or regulatory body or any other person, to the extent required by law, if
any judicial, administrative or governmental proceeding requires disclosure of any Confidential Information, provided that the Receiving Party shall immediately notify the Disclosing Party of such requirement in writing so that the Disclosing Party
may seek an appropriate protective order. If such a disclosure is required, the Receiving Party shall provide all reasonable assistance to the Disclosing Party to obtain the appropriate protective order. 

  

	9.4	The Confidential Information may be disclosed by the Receiving Party to any actual or potential legitimate, customer or supplier of that party, or any person carrying out research
or development on its behalf, or any employee of that party or any Affiliate of that party, to the extent necessary for the purposes of the manufacture and sale of, and any other dealings in Products subject in each case to the party in question
first obtaining and providing the other party with a copy of a written undertaking from the person in question, as nearly as practicable in the terms of this clause, to keep the information confidential and to use it only for the purposes for which
the disclosure is made. 

  

 15 

	9.5	CDT OXFORD may disclose the existence and the principal terms of this Agreement to any potential purchaser or other potential successor in title of all or substantially all of its
business PROVIDED that such disclosure is only for the purposes of the evaluation of CDT OXFORD by such potential purchaser or successor in title, and subject to CDT OXFORD first (a) obtaining a written undertaking from the person in question to
keep such information confidential in accordance with the provisions of this clause 9, to not disclose it to any third parties and to use it only for the purposes for which the disclosure is made and (b) notifying the Licensee in writing of the
aforementioned disclosure. 

  

	9.6	The obligations contained in this clause 9 shall not apply to any Confidential Information which: 

  

	 	(a)	at the date of this Agreement or at any time after the date of this Agreement comes into the public domain other than through any act or omission of the Receiving Party or any
Recipient; 

  

	 	(b)	can be shown by the Receiving Party to the reasonable satisfaction of the Disclosing Party to have been known to the Receiving Party prior to it being disclosed by the Disclosing
Party to the Receiving Party; 

  

	 	(c)	subsequently comes lawfully into the possession of the Receiving Party from a third party entitled to disclose the same and free of restrictions on disclosure and use; or

  

	 	(d)	can be shown by the Receiving Party to the reasonable satisfaction of the Disclosing Party to have been independently developed by the Receiving Party without using any Confidential
Information of the Disclosing Party; or 

  

	9.7	To secure the confidentiality attaching to the Confidential Information of the Disclosing Party, the Receiving Party shall take reasonable and appropriate measures to safeguard it
against theft, loss or negligent disclosure to others, including but not limited to the same measures as it would take to protect its own confidential information. 

  

	9.8	Each party acknowledges and agrees that in the event of a breach or threatened breach of any of the provisions of this Agreement, the Disclosing Party shall have no adequate remedy
at law and shall therefore, in addition to any other rights or remedies that such Disclosing Party may have at law or in equity, be entitled to injunctive relief to restrain such breach or threatened breach, without the necessity of proving

  

 16 

 damages, posting any bond or other security, and without prejudice to or diminution of any other rights
or remedies which may be available at law or in equity. 
  

	10.	FORCE MAJEURE 

  

	10.1	Neither party shall be deemed to be in breach of this Agreement, or otherwise be liable to the other, by reason of any delay in performance or non-performance of any of its
obligations under this Agreement to the extent that such delay or non-performance is due to any cause beyond its reasonable control including but not limited to any strike, lockout or other form of industrial action (an “Event of Force
Majeure”). 

  

	10.2	The party affected by the Event of Force Majeure shall immediately give the other party written notification of the nature and extent of the Event of Force Majeure and the parties
shall enter into bona fide discussions with a view to alleviating its effects or to agreeing upon such alternative arrangements as may be fair and reasonable. 

  

	11.	NATURE OF AGREEMENT 

  

	11.1	CDT Oxford shall be entitled to transfer both the benefit and burden of this Agreement by way of novation to any Member of CDT Oxford’s Group or to perform any of the
obligations undertaken by it and to exercise any rights granted to it under this Agreement through any Member of CDT Oxford’s Group, provided that any act or omission of any such Member of CDT Oxford’s Group shall, for all the purposes of
this Agreement, be deemed to be the act or omission of CDT Oxford, provided further that any such transferee agree to assume all of the obligations of CDT or CDT Oxford, as the case may be, under this Agreement. 

  

	11.2	Either party may transfer both the benefit and burden of this Agreement by way of a novation to any purchaser or other successor in title (whether by way of a flotation, initial
public offering, reorganisation, amalgamation or otherwise) of all or substantially all of its business, provided that any such transferee agree to assume all of the obligations of CDT or CDT Oxford, as the case may be, under this Agreement.

  

	11.3	Subject to clauses 11.1 and 11.2, this Agreement is personal to each party hereto, who shall not assign, mortgage, charge (otherwise than by floating charge) or (except as expressly
provided herein) sub-license any of its rights hereunder or sub-contract or otherwise delegate any of its obligations hereunder, except with the written consent of the other party (which shall not be unreasonably withheld or delayed).
Notwithstanding 

  

 17 

 the foregoing, Licensee shall be entitled to assign this Agreement to any of its Affiliates without any
requirement to obtain the consent of CDT Oxford. Any transfer or assignment of this Agreement shall not relieve Licensee or CDT Oxford, as the case may be, from any liability or obligation arising on or prior to the date of such transfer.

  

	11.4	Nothing in this Agreement shall create, or be deemed to create, a partnership, or the relationship of principal and agent, between the parties, nor are the parties partners or joint
venturers . 

  

	11.5	Each party hereto warrants to the other party that: 

  

	 	(a)	it has the authority to enter into this Agreement; and 

  

	 	(b)	the execution of, and the performance of its obligations under, this Agreement require no governmental or other approvals or, if required, such approvals have been obtained.

  

	11.6	Neither party hereto shall be liable to the other party for any indirect or consequential losses, damages, costs or expenses incurred by reason of any duty at common law or under
any statute, or any term hereof, whether express or implied by statute, collaterally or otherwise, nor for any loss of profit, business, goodwill, anticipated savings or contracts, however the same may arise and whether occasioned by the negligence,
breach of contract or otherwise of the other party, its servants or agents or otherwise, which arises out of or in connection with this Agreement or its use by the other party. 

  

	11.7	The Licensee hereby agrees to indemnify and keep indemnified CDT Oxford, its servants and agents from and against all actions, claims, costs and demands which may be brought or made
against CDT Oxford and all losses, damages, costs and expenses of any kind suffered by CDT Oxford of whatever nature and howsoever arising in connection with any Product manufactured by or on behalf of the Licensee or any Affiliate, except in the
case of any misrepresentation by CDT Oxford. 

  

	11.8	To the extent permitted by law, the maximum limit of CDT Oxford’s liability under or in connection with this Agreement, whether in contract, tort, negligence, breach of
statutory duty or otherwise shall be such sum as equals the greater of US$500,000 and the amount of royalties in the previous year, except in the case of any misrepresentation by CDT Oxford. 

  

 18 

	11.9	The Licensee acknowledges that it has entered into this Agreement in reliance only upon the representations, warranties and promises specifically contained or incorporated in this
Agreement and, save as expressly set out in this Agreement, CDT Oxford shall have no liability in respect of any other representation, warranty or promise made prior to the date of this Agreement unless it was made fraudulently.

  

	11.10	Except as otherwise expressly set forth herein, CDT Oxford make no representations, extends no warranties of any kind and assumes no responsibility with respect to any use, sale or
other disposition of Dendrimers by Licensee or its customers. CDT Oxford specifically disclaims any and all implied warranties including warranties of merchantability and fitness for a particular purpose. 

  

	11.11	Except as otherwise expressly set forth herein, Licensee makes no representations, extends no warranties whether express or implied of any kind and assumes no responsibility with
respect to any use, sale or other disposition of Product or its customers. Licensee specifically disclaims any and all implied warranties including warranties of merchantability and fitness for a particular purpose. 

  

	12.	GOVERNING LAW AND JURISDICTION 

  

	12.1	This Agreement shall be governed by and construed in accordance with English law. 

  

	12.2	If it is not possible to resolve a disagreement or dispute arising under, out of, or in connection with or in relation to this Agreement through good faith negotiations among the
parties hereto, the matter shall be submitted to a panel of three arbitrators in accordance with the Rules of Arbitration of the International Chamber of Commerce. Licensee shall chose one arbitrator and CDT Oxford shall choose the second
arbitrator. The third arbitrator shall be selected by the first two arbitrators. The arbitration shall take place in Tokyo, Japan, if requested by CDT Oxford, and in London, England, if requested by Licensee. The parties hereto agree that service of
any notices in the course of such arbitration at their addresses as given in this Agreement shall be valid and sufficient. Any award rendered in such arbitration shall be final and binding upon the parties hereto, and judgment upon the award
rendered in the arbitration may be entered in any court having jurisdiction, or application may be made to such court for a judicial acceptance of the award and an order of enforcement, as the case may be. 

  

 19 

	12.3	Unless expressly provided in this Agreement, no term of this Agreement is enforceable pursuant to the Contracts (Rights of Third Parties) Act 1999 by any person who is not a party
to it. 

  

	13.	NOTICES 

  
 Any notice, disclosure or report given under this Agreement shall be in writing (which for such purposes shall include e-mail), in English and legible,
shall be served by hand on a business day at or by being sent by facsimile (with confirmation of receipt) or email on a business day or by being sent by first class post or airmail to the address as given on page 1 or as otherwise notified in
accordance with this clause, and shall be deemed served on the date actually received by the other party. Notices, disclosures and reports shall, if sent to CDT Oxford, be marked for the attention of Stephen Chandler, Director Legal & IP and, if
sent to Licensee, shall be marked for the attention of Toshihiro Ohnishi, Corporate Planning & Coordination Office or, in either case, such other person whose details have been notified to the other party in accordance with this clause. Any
notice provided in accordance with the terms of this clause shall be deemed to have been served at the time of delivery. 
  

	14.	FURTHER ASSURANCE 

  
 After this Agreement has been signed by both parties, each party shall execute such documents and take such steps as the other party may reasonably
require to fulfil the provisions of and to give to each party the full benefit of this Agreement. 
  

	15.	WAIVER 

  

	15.1	The rights, powers and remedies conferred on any party by this Agreement and remedies available to any party are cumulative and are additional to any right, power or remedy which it
may have under general law, this Agreement or otherwise. 

  

	15.2	Any party may, in whole or in part, release, compound, compromise, waive or postpone, in its absolute discretion, any liability owed to it or right granted to it in this Agreement
by any other party or parties without in any way prejudicing or affecting its rights in respect of that or any other liability or right not so released, compounded, compromised, waived or postponed. 

  

	15.3	No delay or omission on the part of any party to this Agreement in exercising any right, power or remedy provided by law or under this 

  

 20 

 Agreement shall impair such right, power or remedy; or operate as a waiver thereof, nor shall the single
or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy. 
  

	16.	SEVERANCE 

  
 To the extent that any provision of this Agreement is found by any court or competent authority to be invalid, unlawful or unenforceable in any
jurisdiction, that provision shall be deemed not to be a part of this Agreement, it shall not affect the enforceability of the remainder of this Agreement nor shall it affect the validity, lawfulness or enforceability of that provision in any other
jurisdiction. 
  

	17.	ANNOUNCEMENTS 

  
 The parties shall make a joint announcement within 30 days of the signature of this Agreement. The text of such announcement shall be agreed by the
parties and it shall not be made public until such agreement is reached. In addition, the parties will use their reasonable endeavours to promote Dendrimer technology for the duration of this Agreement. 
  

	18.	NON SOLICITATION 

  
 Each party hereto agrees that, during the term of this Agreement and for a period of 12 months following the expiration or termination of this Agreement,
it shall not solicit the services (except as contemplated by the Project) or employment of or introduce to another employer either temporarily or permanently, directly or indirectly any person who is employed by the other party or its Affiliates,
and who was or is involved in the Project, and shall use commercially reasonable efforts to ensure that its Affiliates comply with this provision. Each party hereto agrees that if it or its Affiliates breaches this clause, in addition to any other
remedies that may be available to the other party, it shall pay to the other party a sum equivalent to two times the new annual starting salary and benefits of the person concerned. 
  

	19.	ENTIRE AGREEMENT 

  
 This Agreement comprises the entire agreement and understanding of the parties in relation to its subject matter and cancels and supersedes all previous
communications, agreements or understandings with regard to such subject matter. Each parry hereto acknowledges that it has entered into this Agreement in reliance only upon the representations, warranties 
  

 21 

 and promises specifically contained in this Agreement. The parties hereto specifically agree that said
previous communications, agreements, representations, understandings, negotiations, proposals or undertakings shall not be admissible as evidence in any arbitration, litigation or other legal proceeding for interpretation of this Agreement.

  

	20.	MISCELLANEOUS 

  

	20.1	This Agreement may only be varied by an agreement in writing specifically referring to this clause 20.1 and signed by or on behalf of both parties hereto. 

 

	20.2	The parties are not partners or joint venturers nor is either able to act as agent of the other. 

  

	20.3	This Agreement may be executed via facsimile and may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute
one and the same instrument. 

  

 22 

 THIS AGREEMENT has been executed by the authorised signatories of each party on the Effective Date. 
  

			
	CDT Oxford Limited
		
	 By:
	 	  

		
	 Name:
	 	  

		
	 Title:
	 	  

	
	Sumitomo Chemical Co., Ltd.
		
	 By:
	 	  

		
	 Name:
	 	  

		
	 Title:
	 	  

  

 23 

 Schedule 1 
  

							
	 Application/Publication No.

	  	 Title

	  	 Priority date

	  	 Status

	GB0306340.1	  	METHOD FOR THE PRODUCTION OF METAL COMPLEXES	  	20/03/03	  	P: GB
				
	WO03/008515	  	TERTIARY DIAMINES CONTAINING HETEROCYCLIC GROUPS AND THEIR USE IN ORGANIC ELECTROLUMINESCENT DEVICES	  	17/07/01	  	P: WO
				
	WO03/044877	  	LIGHT EMITTING DEVICE AND COMPOUNDS FOR USE THEREIN	  	16/11/01	  	P: WO
				
	PCT/03/GB/00857	  	PHOSPHORESCENT COMPOSITIONS AND ORGANIC LIGHT EMITTING DEVICES CONTAINING THEM	  	04/03/02	  	P: WO
				
	PCT/03/GB/0899	  	POLYMERISABLE COMPOSITIONS AND ORGANIC LIGHT-EMITTING DEVICES CONTAINING THEM	  	09/03/02	  	P: WO

  
 Status: P: Pending, G: Granted

  

 33 

 Schedule 2 
  

							
	 Application/Publication No.

	  	 Title

	  	 Priority date

	  	 Status

	 WO98/55561
	  	ORGANOMETALLIC COMPLEXES	  	02/06/97	  	G: EP P: JP,US
				
	 WO99/21935
	  	LIGHT EMITTING DENDRIMERS AND DEVICES	  	23/10/97	  	P: CN, EP, JP, KR, US
				
	 WO00/18851
	  	DIVALENT LANTHANIDE METAL COMPLEXES	  	25/09/98	  	G: USP: EP, JP
				
	 WO01/59030
	  	IMPROVED DENDRIMERS	  	09/02/00	  	P: EP, JP, US
				
	 WO02/20692
	  	PYRAZOLONE LANTHANIDE COMPLEXES	  	08/09/00	  	P: GB, US
				
	 WO02/67343
	  	ARYL-ARYL DENDRIMERS	  	20/02/01	  	P: EP, JP, US
				
	 WO02/66575
	  	ASYMMETRIC DENDRIMERS	  	20/02/01	  	P: EP, JP, US
				
	 WO02166552
	  	METAL CONTAINING DENDRIMERS	  	20/02/01	  	 P: CA, CN, EP, IN,
 JP, KR,
SG, US

				
	 WO02/68560
	  	LUMINESCENT POLYMERS	  	26/02/01	  	P: EP, JP, US
				
	 PCT/03/GB/01189
	  	RHENIUM COMPOUNDS	  	15/03/02	  	P: EP, JP, US
				
	 PCT/03/GB/01132
	  	PHOSPHORESCENT DENDRIMERS	  	18/03/02	  	P: WO
				
	 GB0220080.6
	  	BLENDED DENDRIMERS	  	29/08/02	  	P: WO
				
	 GB0219987.5
	  	DOUBLE DENDRONS	  	28/08/02	  	P: WO
				
	 GB0220092.1
	  	REACTIVE DENDRIMERS	  	28/08/02	  	P: WO
				
	 GB0222268.5
	  	FLUORENE-CONTAINING DENDRIMERS	  	25/09/02	  	P: GB

  
 Status: P: Pending, G: Granted

  

 34Patent and Co-Ownership Agreement, dated July 5, 2004

 Exhibit 10.23 
  
 DATED 5 July 2004 
  
 (1) ISIS INNOVATION LIMITED 
  
 (2) CDT OXFORD LIMITED 
  
 (3) THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD 
  
 (4) THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS 
  

  
 PATENT CO-OWNERSHIP AGREEMENT 
  

  
 CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED FROM THIS DOCUMENT. SUCH
OMISSIONS ARE NOTED BY “[**]”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION. 
  

 THIS AGREEMENT dated July 5, 2004 (the “Effective Date”) is made between: 
  

	(1)	ISIS INNOVATION LIMITED whose registered office is at University Offices, Wellington Square, Oxford OX1 2JD England (“Isis”) and 

  

	(2)	CDT OXFORD LIMITED whose registered office is at Greenwich House, Madingley Rise, Madingley Road, Cambridge CB3 0TX, England (“CDT”)

  

	(3)	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD whose administrative offices are at Wellington Square, Oxford OX1 2JD, England (“Oxford”)

  

	(4)	THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS incorporated by the Universities (Scotland) Act 1899, as amended by the Universities (Scotland) Act 1966 and having its
principal office at College Gate, North Street, St Andrews, Fife KY16 9AJ, Scotland (“St Andrews”) 

  
 WHEREAS 
  

	(A)	CDT, Isis, Oxford and St Andrews have entered into the Research Agreement. It is expected that cooperation under the Research Agreement may give rise to Inventions to which
Inventors from more than one party to the Research Agreement have contributed. 

  

	(B)	The Parties hereby desire to determine the ownership of such Inventions, the pursuit and maintenance of any patent applications and/or patents resulting from such Inventions and any
consideration due between the Parties on the exploitation of such patents/applications. 

  

	(C)	Isis, Oxford, St Andrews and Opsys Limited entered into a Licence of Technology dated 21 January 2002 which was novated from Opsys Limited to CDT by a Novation and Variation
Agreement dated 22 October 2002. These agreements govern the licence of patents/applications in the ownership of one or more of Isis, Oxford and St Andrews. 

  

	(D)	The Parties wish to provide a single mechanism for the payment of royalties in respect of the exploitation of patents/applications under the Licence of Technology as novated and
varied and in respect of the exploitation of jointly owned patents arising pursuant to the Research Agreement. 

  

 2 

 OPERATIVE PROVISIONS 
  

	1.	INTERPRETATION AND CONDITION PRECEDENT  

  

	1.1	Interpretation 

  
 In this Agreement: 
  

			
	 “Affiliate”
	  	Means any corporation which directly controls, is controlled by, or is under common control with Oxford, St Andrews, Isis or CDT as the case may be.
		
	 “Agreement”
	  	Means this agreement and its Schedules.
		
	 “Field”
	  	Means light emitting devices, for displays, lighting, and Photovoltaic Devices and the supply of Materials for displays, lighting or Photovoltaic Devices.
		
	 “Gross Receipts”
	  	Means any gross revenue received from a third party in respect of licenses granted in accordance with clauses 4.1 or 4.2 less any rebates or amounts returned to such third parties which are
related to such revenue and less any deductions pursuant to clause 5.13.
		
	 “Gross Sales”
	  	Means the price paid to CDT by third parties upon sale or other transfer of Products or Materials less any allowances for returns or lost or damaged merchandise and any discounts or rebates
granted to customers on account of quantity purchased or promptness of payment. Where any Product is sold or otherwise transferred to a third party in the form of an article comprising the Product itself and further components or where Products or
articles comprising Products and further components are transferred otherwise than on arm’s length terms the Parties will agree a fair value for the Products concerned.
		
	 “Invention”
	  	Means any invention which is jointly made by CDT and any one or more of the other parties and is referred to in any of the Schedules that may be added to this Agreement from time to
time.

  

 3 

			
	 “Inventor”
	  	Means the Person defined as an inventor on any of the Inventions defined in the Schedules.
		
	 “Material”
	  	Means a material covered by any claim(s) in any Patent(s) or other patents/applications licensed to CDT under the Licence of Technology.
		
	 “Nominated
 University
 Representative”
	  	Means that organisation nominated in writing by Isis, Oxford and St Andrews to deal with any matters relating to a particular Invention.
		
	 “Other Products”
	  	Means Products or Materials which are not Solution Processable Phosphorescent Materials, SPPM Products or PV Products.
		
	 “Parties”
	  	Means the parties to this Agreement namely Isis, CDT, Oxford, St Andrews.
		
	 “Patent”
	  	Means any patent or patent application which is filed (or to be filed) in the joint names of CDT and any one or more of the other parties in respect of any of the Inventions.
		
	 “Person”
	  	Includes any person, firm or company or group of persons or unincorporated body.
		
	 “Photovoltaic
 Device”
	  	Means photovoltaic devices whether for power generation or photodetection.
		
	 “PD”
	  	                [**]
		
	 “PM”
	  	                [**]

  

 4 

			
	 “PL”
	  	            [**]
		
	 “Product”
	  	Means a light-emitting device (whether for display or lighting) or a Photovoltaic Device falling within the scope of any claim(s) in any Patent(s) or other patent/application licensed to CDT
under the Licence of Technology.
		
	 “PV Products”
	  	Means Products which are Photovoltaic Devices, but excluding any part of a Product which does not perform the essential function of a Photovoltaic Device; and Materials that are used in
providing the essential function of a Photovoltaic Device.
		
	 “Relevant Licence”
	  	Means (1) in the case of the application of the formula to Gross Receipts, the licence from CDT or its Affiliates to a licensee in respect of patents/applications including any Patents or other
patents licensed to CDT under the Licence of Technology; or (2) in the case of the application of the formula to Gross Sales, the notional licence that CDT or its Affiliates would require if CDT or its Affiliates were deemed for these purposes to be
an independent third party at arm’s length to CDT.
		
	 “Relevant Patents”
	  	Means patents or patent applications owned or licensed to a party (and/or in the case of CDT, its Affiliates) which are directed to Solution Processable Phosphorescent Materials or devices
containing the same.
		
	 “Relevant PV 
 Patents”
	  	Means patents or patent applications owned or licensed to a party (and/or in the case of CDT its Affiliates) which are directed to Photovoltaic Devices or devices containing the
same.
		
	 “Research 
 Agreement”
	  	Means the research agreement relating to Solution Processable Phosphorescent Materials to be entered into by the Parties.
		
	 “Schedule”
	  	Means any schedule to this Agreement in the agreed form in respect of an Invention and signed by each of the Parties as set out in the annex hereto.
		
	 “Solution 
 Processable 
 Phosphorescent 
 Materials”
	  	Means Materials which are soluble in organic solvents and are intended to be deposited from solution and which will emit light from the triplet state including metal-to-ligand charge transfer
states (whether for use in lighting, displays or Photovoltaic Devices).
		
	 “SPPM Products”
	  	Means Products comprising Solution Processable Phosphorescent Materials.

  

 5 

	1.2	Interpretation 

  
 The singular includes the plural and vice versa. 
  

	1.3	Condition Precedent 

  
 The obligations of the Parties under this Agreement are conditional on the Parties entering into the Research Agreement on or before 5 July 2004. If the
Parties have not entered into the Research Agreement on or before 5 July 2004 this Agreement will have no effect, and no Party shall have any right or claim against any other Party under this Agreement. 
  

	2.	PATENT APPLICATION 

  

	2.1	The Parties agree that any inventions which fall under the definitions within the Research Agreement of Joint Arising IP or Jointly Developed Arising IP and which arise pursuant to
the Research Agreement shall be owned jointly by those Parties developing the same as tenants in common in equal shares, save that in the case of any share which would otherwise be owned by Oxford, such share shall be owned by Oxford or Isis as
appropriate. 

  

	2.2	Any invention which any of the Parties shall determine shall be of commercial value shall be recorded in writing and shall be scheduled to this Agreement in the form set out in the
Annex. 

  

	2.3	The Parties agree that CDT will, in consultation with Isis, Oxford and St Andrews, apply for the Patents in the joint names of the owners of the relevant Inventions, and shall
prosecute and maintain the Patents seeking the broadest monopoly which is reasonable and consistent with validity. 

  

	2.4	CDT shall diligently pursue the grant of Patents in respect of each of the Inventions and Isis, Oxford and St Andrews, at the reasonable request of CDT, agree to execute all such
documents and do all such acts and things as may be necessary for the purpose of clause 2.3. 

  

	2.5	All fees and expenses relating to the filing and prosecution of the Patents shall be borne by CDT and CDT shall reimburse all disbursements paid by Isis, Oxford and St Andrews in
discharging their obligations under clause 2.4. 

  

	2.6	If, at any time, any of Isis, Oxford, St Andrews or CDT indicates to the others by notice in writing that it no longer desires to apply for, pursue or maintain any of the Patent(s)
and within one month of such notice one or more of the other parties notifies such party of its/their willingness to take over the rights of such party in the relevant Patent(s) (or Inventions relating thereto), the first mentioned party shall
assign to the other(s) the relevant Patent(s) (or Inventions relating thereto) without any payment by such party. The first mentioned party shall, at the expiration of one month from the date of its notice: 

  

	 	2.6.1	cease to be liable to bear the fees and expenses referred to in clause 2.5 (if any) relating to the relevant Patent (or Invention relating thereto); 

  

 6 

	 	2.6.2	cease to be eligible to receive any proportion of Gross Sales or Gross Receipts in accordance with clause 5 relating to the relevant Patent (or Invention relating thereto); and

	 	2.6.3	cease to have any control over the exploitation of the relevant Patent (or Invention thereto) either within or outwith the Field. 

  

	3.	EXPLOITATION OF PATENT RIGHTS: RIGHTS OF USE 

  

	3.1	Isis, Oxford and St Andrews shall be entitled, on a royalty free basis, to use the Patent(s) for academic and research purposes (including such research which benefits from third
party grant funding, but not including such research which is commercially sponsored unless such research is outside the Field) within their respective institutions. All such rights shall survive the termination or expiration of this Agreement.

  

	3.2	Should CDT cease to sponsor research at either Oxford or St Andrews or both then CDT may, in its absolute discretion, authorise Oxford and St Andrews to use the Patent(s) for
research within the Field commercially sponsored by a third party. Such authorisation will only effective if it is in writing and signed by the Chief Executive of CDT. 

  

	3.3	Subject to the provisions of clause 5, CDT shall be entitled to manufacture, have made, sell, import or otherwise dispose of Products and Materials in the Field under the Patent(s).

  

	4.	EXPLOITATION OF PATENT RIGHTS: RIGHTS TO LICENCE 

  

	4.1	Subject to the provisions of clause 5, CDT consents to exclusive right of Isis, Oxford and St Andrews acting through the Nominated University Representative to grant licence(s)
(with the right to sub license) under the Patents globally outside the Field provided that immediately following the grant of each licence, the Nominated University Representative notifies CDT in writing of the name and address of the licensee, the
technology licensed, the intended field and/or applications licensed and the duration of the licence. CDT accepts that Isis, Oxford and St Andrews will not be responsible in any way for the nature, extent or effectiveness of the exploitation and
agrees immediately to pass on to the Nominated University Representative any requests for information they receive about any Invention outside the Field. 

  

	4.2	Subject to the provisions of clause 5, Isis, Oxford and St Andrews consent to the exclusive right of CDT to grant licences (with the right to sub license) under the Patents globally
within the Field provided that immediately following the grant of each licence, CDT notifies the Nominated University Representative in writing of the name and address of the licensee, the technology licensed, the intended field and/or applications
licensed and the duration of the licence. Isis, Oxford and St Andrews accept that CDT will not be responsible in any way for the nature, extent or effectiveness of the exploitation and agree immediately to pass on to CDT any requests for information
they receive about the Invention within the Field. 

  

 7 

	4.3	The parties agree that they will notify each other in writing of any disputes arising out of or in connection with licences granted under clauses 4.1 and 4.2 and of which the party
becomes aware. In the event of such a notice being given, the parties will agree the most appropriate course of action and act accordingly. In the event the parties are unable to decide the most appropriate course of action the party who is the
licensor under the licence in dispute will be entitled to take such action it decides is appropriate, (if any), provided that such party indemnifies and holds the other party (and where the other party is Isis, also Oxford and St Andrews) harmless
against all costs (including lawyers’ and patent agents’ fees and expenses), claims, demands and liabilities arising out of or consequent upon such course of action. 

  

	5.	REVENUE SHARING OF GROSS SALES AND GROSS RECEIPTS 

  

	5.1	In respect of the manufacture, sale or other transfer to third parties by or for CDT or any Affiliate of CDT of SPPM Products or Solution Processable Phosphorescent Materials
pursuant to clause 3.3 of this Agreement CDT shall pay to the Nominated University Representative: 

  

	 	i)	royalties of PD in respect of Gross Sales
directly attributable to the sale of such SPPM Products; 

  

	 	ii)	royalties of PM in respect of Gross Sales
directly attributable to the sale of such Solution Processable Phosphorescent Materials. 

  

	5.2	In respect of the grant of licences by CDT to third parties to manufacture, have made, sell, import or otherwise dispose of SPPM Products or Solution Processable Phosphorescent
Materials pursuant to clause 4.2 of this Agreement CDT shall pay to the Nominated University Representative: 

  

	 	i)	royalties of PD in respect of Gross Receipts
obtained from the licensing of such SPPM Products and directly attributable thereto; and 

  

	 	ii)	royalties of PM in respect of Gross Receipts
obtained from the licensing of such Solution Processable Phosphorescent Materials and directly attributable thereto. 

  

	5.3	In respect of the exercise of its rights under clauses 3.3 and 4.2 in relation to PV Products, CDT shall pay royalties in accordance with clauses 5.1 and 5.2 above as appropriate
save that the references to Relevant Patents in the relevant formulae shall be deemed for the purposes of this clause 5.3 to be references to Relevant PV Patents and Gross Receipts shall be deemed to be only those receipts directly attributable to
such PV Products. 

  

	5.4	In respect of the exercise of its rights under clauses 3.3 or 4.2 within the Field in relation to Other Products, CDT shall pay royalties of PD in respect of Gross Sales or Gross Receipts (as appropriate) which are directly attributable to the sales or licensing of such Other Products (whether
Products or Materials) save that in the formula PD, [**]. The values of [**] shall be reviewed annually having
regard to new schedules which may be added either to this Agreement or the Licence of Technology and such values may, with the consent of the parties, be amended. 

  

 8 

	5.5	In consideration of the right to licence the Patents granted under clause 4.1 the Nominated University Representative shall pay to CDT royalties of PL in respect of Gross Receipts obtained from the licensing of such Patents. 

  

	5.6	Within thirty (30) days after each biannual anniversary of the Effective Date, the royalty generating party will supply the other party with a statement of all Gross Sales and Gross
Receipts during that half year, accompanied by a calculation of the percentage due to the other party. The statement will show the Gross Sales and/or Gross Receipts in pounds sterling. The other party will then issue the royalty generating party
with an invoice for the percentage due to them, and the royalty generating party will settle that invoice within thirty (30) days after its receipt. 

  

	5.7	All payments provided for under this clause 5 shall be made in pounds sterling (or any currency replacing pounds sterling) without any deductions apart from any tax which is
required to be withheld under applicable local law. Any change of currency made to calculate sales for the purpose of this clause 5 shall be determined as at the last business day of each quarter, using the average of the average daily buying and
selling rates quoted by Barclays Bank plc during that quarter. Where the payer is required to withhold tax under applicable local law the payer shall deduct such tax, pay it to the relevant taxing authority, and supply the payee with a Certificate
of Tax Deduction at the time of payment to the payee. The Nominated University Representative and CDT shall co-operate under any applicable Double Taxation Treaty so that, if possible, payments are made gross or, if payment gross is not possible,
the Nominated University Representative obtains appropriate relief under the Treaty. 

  

	5.8	Where under English law income tax is required to be deducted from the percentage due to the receiving party, the paying party will make the deduction, account to the UK Inland
Revenue, and issue the receiving party with a tax deduction certificate. 

  

	5.9	Oxford, St Andrews and Isis will keep proper books and records containing all data necessary for the calculation of CDT’s revenue share. Such books and records must be kept for
a period of at least six (6) years. On written request, Oxford, St Andrews and Isis will supply CDT with a statement of such accounts, certified as correct by the Managing Director of Isis and/or the Finance Directors of Oxford and St Andrews
provided that none of Oxford, St Andrews or Isis shall be obliged to provide more than one such statement in any 12 month period. CDT may, through an independent certified accountant, audit all such accounts on at least 30 days’ written notice
no more than once each fiscal year for the purpose of determining the accuracy of the report. Should the audit reveal a discrepancy in favour of CDT by more than 10% then the cost of the audit will be borne by Oxford, St Andrews and Isis. If the
discrepancy is less than 10% then the cost will be borne by CDT. 

  

	5.10	CDT will keep proper books and records containing all data necessary for the calculation of Isis’, Oxford’s and St Andrews’ revenue shares. Such books and records
must be kept for a period of at least six (6) years. On written request, CDT will supply Oxford, St Andrews and 

  

 9 

 Isis with a statement of such accounts, certified as correct by the Managing Director of CDT provided
that CDT shall not be obliged to provide more than one such statement in any 12 month period. The Nominated University Representative may, through an independent certified accountant, audit all such accounts on at least 30 days’ written notice
no more than once each fiscal year for the purpose of determining the accuracy of the report. Should the audit reveal a discrepancy in favour of Oxford, St Andrews and Isis by more than 10% then the cost of the audit will be borne by CDT. If the
discrepancy is less than 10% then the cost will be borne by Oxford, St Andrews and Isis. 
  

	5.11	In the event that full payment of any amounts due from one party to another under this Agreement is not made by any of the dates stipulated, the defaulting party shall be liable to
pay interest on the amount unpaid at the rate of two per cent (2%) over the base rate for the time being of Barclays Bank plc, from the date when payment was due until the day of actual payment. 

  

	5.12	Neither Isis nor Oxford nor St Andrews shall pay revenue to individual employees of CDT. The payment of revenue to CDT under this clause 5 constitutes the Oxford, St Andrews and
Isis full financial commitment to CDT and its employees. CDT shall not pay revenue to individual employees of Oxford or St Andrews. The payment of revenue to the Nominated University Representative under this clause 5 constitutes CDT’s full
financial commitment to Isis, Oxford and St Andrews and their employees. 

  

	5.13	[**] 

  

	5.14	[**] 

  

	5.15	If CDT exploits any Patent or patent licensed to it from Isis, Oxford or St Andrews in any way other than those anticipated by this clause 5, then the Parties shall meet to discuss
the manner of such exploitation and any effect thereof upon the terms of this Agreement in good faith. 

  

	5.16	Clauses 5.1 to 5.15 above shall be the sole terms governing the payment of royalties by CDT to Isis, Oxford and St Andrews under both this Agreement and the Licence of Technology
and it is agreed that clauses 6.1 to 6.14 of the Licence of Technology shall be of no further effect provided always that in relation to any technology (other than an Invention) which is licensed to CDT after the date of this Agreement and which has
not 

  

 10 

 arisen from research funded by CDT, the Nominated University Representative shall be at liberty to seek
to negotiate the payment by CDT of a reasonable signing fee for such technology and the Parties shall negotiate such signing fee in good faith. 
  

	6.	INFRINGEMENT AND DISPUTES 

  

	6.1	Each party will notify the others in writing of any misappropriation or infringement of the Patents of which the party becomes aware. 

  

	6.2	CDT has the first right (but is not obliged) to take legal action at its own cost against any misappropriation or infringement of the Patents. CDT must discuss any proposed legal
action with the Nominated University Representative prior to the legal action being commenced. 

  

	6.3	If CDT takes legal action under clause 6.2, CDT will: 

  

	 	i)	indemnify and hold Isis, Oxford and St Andrews harmless against all costs (including lawyers’ and patent agents’ fees and expenses), claims, demands and liabilities
arising out of or consequent upon such activities and will satisfy any invoice received from the Nominated University Representative in respect of such costs, claims, demands and liabilities within thirty (30) days of receipt;

  

	 	ii)	treat any award of damages (including, without limitation, punitive damages) as Gross Sales for the purposes of clause 5.1; and 

  

	 	iii)	keep the Nominated University Representative regularly informed of the progress of the legal action, including, without limitation, any claims affecting the scope of any Patent.

  

	6.4	If CDT has notified the Nominated University Representative in writing that it does not intend to take any action in relation to the misappropriation or infringement, any of Isis,
Oxford or St Andrews may take such legal action at its own cost and will: 

  

	 	i)	indemnify and hold CDT harmless against all costs (including lawyers’ and patent agents’ fees and expenses), claims, demands and liabilities arising out of or consequent
upon such activities and will satisfy any invoice received from CDT in respect of such costs, claims, demands and liabilities within thirty (30) days of receipt; and 

  

	 	ii)	keep CDT regularly informed of the progress of the legal action, including, without limitation, any claims affecting the scope of any Patent. 

  

	7.	DUTY OF GOOD FAITH 

  
 Each party shall at all times act in good faith towards the other in relation to the Patents and their use, enjoyment and exploitation. In the event that either party shall receive any information which can reasonably
be said to be material to the subject matter of this Agreement or any transaction concerning the Patents he shall forthwith communicate such information to the other party. 
  

 11 

	8.	CONFIDENTIALITY 

  

	8.1	Subject to clauses 8.2, 8.3 and 8.4, each party undertakes to the other that it shall use reasonable endeavours to keep secret and confidential the Invention and all know-how and
other technical information communicated to it by the other in relation to the subject matter of this Agreement (“Confidential Information”). 

  

	8.2	The provisions of clause 8.1 shall not apply to any Confidential Information which: 

  

	 	(a)	at the date of this Agreement or at any time after the date of this Agreement comes into the public domain other than through breach of this Agreement by the party receiving such
information (“Receiving Party”) 

  

	 	(b)	can be shown by the Receiving Party to the reasonable satisfaction of the party disclosing such information (“Disclosing Party”) to have been known to the Receiving
Party prior to it being disclosed by the Disclosing Party to the Receiving Party; 

  

	 	(c)	subsequently comes lawfully into the possession of the Receiving Party from a third party entitled to disclose the same; 

  

	 	(d)	can be shown by the Receiving Party to the reasonable satisfaction of the Disclosing Party to have been independently developed by the Receiving Party without using any Confidential
Information of the Disclosing Party; or 

  

	 	(e)	is required to be disclosed by any law or by any governmental or other body of competent jurisdiction. 

  

	8.3	Notwithstanding clause 8.1, CDT may disclose the Invention(s) and Patents(s) and any related know-how and other technical information, including by means of providing samples of
materials, to any actual or potential legitimate licensee, customer or supplier or any person carrying out research or development on CDT’s behalf to the extent necessary for the purposes of the development and/or exploitation of the
Invention(s) and/or Patent(s) within the Field, subject in each case to CDT ensuring that the recipients of such information do so under a duty of confidence 

  

	8.4	Notwithstanding clause 8.1, Oxford, St Andrews and Isis may disclose the Invention(s) and Patents(s) and any related know-how and other technical information to any actual or
potential legitimate licensee, customer or supplier or any person carrying out research or development on behalf of Isis, Oxford and St Andrews to the extent necessary for the purposes of the development and/or exploitation of the Invention(s)
and/or Patent(s) outside the Field, subject in each case to Oxford, St Andrews and Isis ensuring that the recipients of such information do so under a duty of confidence. 

  

 12 

	8.5	In accordance with normal academic practice, all employees, students, agents or appointees of Isis, Oxford, St Andrews and CDT shall be permitted: 

  
 i) following the procedures laid down in clause 8.6, to publish work
undertaken on or in connection     with the Invention (the “Results”); and 
  
 ii) to discuss the Results in internal seminars, and to give instruction on questions related to such work provided that the persons receiving
    information relating to such Results do so under a duty of confidence. 
  

	8.6	Isis, Oxford, St Andrews and CDT (in this clause, the “Publisher”) will use all reasonable endeavours to submit Results intended for publication to the other party
(in this clause, the “Reviewer”) in writing not less than thirty (30) days in advance of the submission for publication. The Reviewer may request the Publisher to delay submission for publication if in the Reviewer’s opinion
such delay is necessary in order to seek patent or similar protection for the Results. A delay imposed on submission for publication as a result of a requirement made by the Reviewer shall not last longer than is absolutely necessary to seek the
required protection; and therefore shall not exceed six (6) months from the date of receipt of the Results by the Reviewer. Notification of the requirement for delay in submission for publication must be received by the Publisher within thirty (30)
days after the receipt of the Results by the Reviewer, failing which the Publisher shall be free to assume that the Reviewer has no objection to the proposed publication. For the avoidance of doubt, nothing in this Agreement shall prevent or hinder
registered students of Oxford or St Andrews from submitting for degrees of Oxford or St Andrews respectively theses based on Results or from following Oxford’s or St Andrews’ respective procedures for examinations and for admission to
postgraduate degree status. 

  

	9.	GENERAL 

  

	9.1	The parties agree that the Licence of Technology shall be amended by the deletion of clause 7.4 save that within sixty (60) days of the Effective Date, and each subsequent
anniversary of the Effective Date CDT shall provide a brief progress report on all matters relating to the marketing of licences for Products and Materials which are not confidential. 

  

	9.2	This Agreement will take effect on the Effective Date and will continue in force until the last of the Patents has ceased to be in force. 

  

	9.3	Nothing in this Agreement shall constitute or give rise to the creation of a partnership as between the parties. 

  

	9.4	No party shall assign, transfer, charge, encumber or otherwise deal with any of the Patents or the whole or any part of or any of its rights or obligations under this Agreement
without the consent of all other parties save that CDT may assign its interest in the Patents to its 

  

 13 

 Affiliates or its holding company or to any purchaser or other successor in title (whether by way of a
flotation, initial public offering, reorganisation, amalgamation or otherwise) of all or substantially all of its business. 
  

	9.5	CDT agrees to indemnify Isis, Oxford and St Andrews and hold Isis, Oxford and St Andrews harmless from and against any and all claims, damages and liabilities:

  
 i) asserted by third parties (including claims
for negligence) which arise directly or indirectly from the use of the Invention or the marketing of Products or Materials by CDT or its Affiliates or its licensees; or 
  
 ii) arising directly or indirectly from any breach by CDT of this Agreement. 
  

	9.6	The liability of any party for any breach of this Agreement, or arising in any other way out of the subject-matter of this Agreement, will not extend to incidental or consequential
damages or any loss of profits. 

  

	9.7	The maximum liability of Isis, Oxford and St Andrews to CDT under or otherwise in connection with this Agreement or its subject-matter (including, without limitation, clause 4.3)
will not exceed the return of all royalties paid to Isis, Oxford and St Andrews under clause 5. 

  

	9.8	The maximum liability of CDT to Isis, Oxford and St Andrews under or otherwise in connection with this Agreement or its subject-matter will not exceed the amount of all royalties
paid to Isis, Oxford and St Andrews under clause 5 or $500,000 whichever is the greater. 

  

	9.9	CDT undertakes to make no claim in connection with this Agreement or its subject matter against any employee, student, agent or appointee of Isis, Oxford or St Andrews (apart from
claims based on fraud or wilful misconduct). This undertaking is intended to give protection to individuals: it does not prejudice any right which CDT might have to claim against Isis, Oxford or St Andrews. 

  

	9.10	Save as set out in clauses 9.11 and 9.12, this Agreement is not transferable, and neither party may purport to assign it (in whole or in part) without the prior written consent of
the other. The parties to this Agreement do not intend that by virtue of the Contracts (Rights of Third Parties) Act 1999 any of the terms of this Agreement other than clauses 3.1 and 9.9 hereof should be enforceable by a person who is not a party
to it. 

  

	9.11	The parties shall be entitled to transfer both the benefit and burden of this Agreement by way of novation to any Affiliate or to perform any of the obligations undertaken by it and
to exercise any rights granted to it under this Agreement through any Affiliate. 

  

	9.12	The parties may transfer both the benefit and burden of this Agreement by way of a novation to any purchaser or other successor in title (whether by way of a flotation, initial
public offering, reorganisation, amalgamation or otherwise) of all or substantially all of its business. 

  

 14 

	9.13	This Agreement constitutes the entire agreement between the parties relating to co-ownership of the Patents. 

  

	9.14	Any variation of this Agreement shall be in writing and signed by authorised representatives of the parties. 

  

	9.15	If any one or more clauses or sub-clauses of this Agreement would result in this Agreement being prohibited pursuant to any competition law, then it or they shall be deemed to be
omitted. The parties shall uphold the remainder of this Agreement, and shall negotiate an amendment which, as far as legally feasible, maintains the economic balance between the parties. 

  

	9.16	This Agreement is governed by English law and the parties submit to the exclusive jurisdiction of the English Courts for the resolution of any dispute which may arise out of or in
connection with this Agreement. 

  

 15 

 AS WITNESS the hands of authorised signatories for the parties on the date first mentioned above. 
  
 Signed for and on behalf of ISIS INNOVATION LTD 
  
 Name: Mr. T. Hockaday 
  
 Position: Executive Director 
  
 Signature: /s/ Mr. T. Hockaday 
  
 Signed for and on behalf of CDT OXFORD LTD 
  
 Name: S.B.J. Chandler 
  
 Position: Director 
  
 Signature: /s/ S.B.J. Chandler 
  
 Signed for and on behalf of THE CHANCELLOR, 
 MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD 
  
 Name: Pierre
M. Epinasse 
  
 Position: Deputy Director 
  
 Signature: /s/ Pierre M. Epinasse 
  
 Signed for and on behalf of THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS

  
 Name: Alistair B. Main 
  
 Position: Associate Director 
  
 Signature: /s/ Alistair B. Main 
  

 16 

 APPENDIX 
  

Pro-forma Schedule 
  

			
	 SCHEDULE NUMBER
	  	Effective Date:

  
 Jointly Owned Technology (clause
1): 
  

	(a)	the invention (the “Invention”) described in British Priority Patent Application No. GB<            
> or International Patent Application No. PCT/GB<             >, which was filed on
<                                 > with the priority date
<                     > and entitled
<                     >;1 

  

	(b)	unpatented or unpatentable works and designs ancillary to the Invention, which have been or are created by the inventors named in the above Application (the
“Inventors”), and which have been or are communicated to the Licensee by the Inventors or the Licensor; 

  

	(c)	confidential information so communicated to the Licensee, and concerned with or related to the Invention or the practice of the Invention; and technology so communicated to the
Licensee pursuant to Clause 4.6 of this Agreement. 

  
 Isis Reference (if applicable): 
  
 Applicable Research
Contract: 
  
 Nominated University Representative 
  
  

			
	 SIGNED for and on behalf of CDT Oxford
	 	SIGNED for and on behalf of Isis Innovation
	 Limited
	 	Limited
		
	 Name:
	 	Name:
		
	 Position:
	 	Position:
		
	 Signature:
	 	 Signature:
  

	 SIGNED for and on behalf of the Chancellor,
 Masters and Scholars of the University of Oxford
	 	 SIGNED for and on behalf of the University
 Court of the University of St Andrews

		
	 Name:
	 	Name:
		
	 Position:
	 	Position
		
	 Signature:
	 	Signature

  

	1	Insert appropriate type of patent application with details 

  

 17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}]]